New IPF drug passes first safety check in small trial

NCT ID NCT05895565

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tested an experimental drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. The main goal was to see if the drug is safe and how the body handles it. Participants received either the drug or a placebo, and researchers monitored side effects and lung function. This is an early-phase trial, so it focuses on safety rather than proving the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IPF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, 100029, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, 210008, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, 200030, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.